BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31048902)

  • 1. Hybrid FDG PET/MRI vs. FDG PET and CT in patients with suspected dementia - A comparison of diagnostic yield and propagated influence on clinical diagnosis and patient management.
    Kaltoft NS; Marner L; Larsen VA; Hasselbalch SG; Law I; Henriksen OM
    PLoS One; 2019; 14(5):e0216409. PubMed ID: 31048902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
    Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI.
    Schaarschmidt BM; Heusch P; Buchbender C; Ruhlmann M; Bergmann C; Ruhlmann V; Schlamann M; Antoch G; Forsting M; Wetter A
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):92-102. PubMed ID: 26243264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management impact of FDG-PET in dementia: results from a tertiary center memory clinic.
    Elias A; Woodward M; Rowe CC
    J Alzheimers Dis; 2014; 42(3):885-92. PubMed ID: 24961944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in penile cancer.
    Zhang S; Li W; Liang F
    Oncotarget; 2016 Jul; 7(30):48600-48606. PubMed ID: 27203206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer.
    Kim HJ; Cho A; Yun M; Kim YT; Kang WJ
    Ann Nucl Med; 2016 Feb; 30(2):104-13. PubMed ID: 26546334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
    Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
    Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the clinical impact of 2-[18F]FDG-PET and cerebrospinal fluid biomarkers in patients suspected of Alzheimer's disease.
    Gjerum L; Andersen BB; Bruun M; Simonsen AH; Henriksen OM; Law I; Hasselbalch SG; Frederiksen KS
    PLoS One; 2021; 16(3):e0248413. PubMed ID: 33711065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous whole-body time-of-flight 18F-FDG PET/MRI: a pilot study comparing SUVmax with PET/CT and assessment of MR image quality.
    Iagaru A; Mittra E; Minamimoto R; Jamali M; Levin C; Quon A; Gold G; Herfkens R; Vasanawala S; Gambhir SS; Zaharchuk G
    Clin Nucl Med; 2015 Jan; 40(1):1-8. PubMed ID: 25489952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
    Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
    Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
    Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M
    Haematologica; 2007 Jan; 92(1):50-5. PubMed ID: 17229635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
    Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
    Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis.
    King AD; Ma BB; Yau YY; Zee B; Leung SF; Wong JK; Kam MK; Ahuja AT; Chan AT
    Br J Radiol; 2008 Apr; 81(964):291-8. PubMed ID: 18344274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
    Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
    Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT.
    Kubota K; Yokoyama J; Yamaguchi K; Ono S; Qureshy A; Itoh M; Fukuda H
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):590-5. PubMed ID: 14722678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.